Want to see AXGN full AI Analyst Report?
AXGN Stock Chart & Stats
$39.49
-$0.24(-0.60%)
At close: 4:00 PM EDT
$39.49
-$0.24(-0.60%)
Day’s Range― - ―
52-Week Range$12.39 - $46.95
Previous CloseN/A
Volume750.55K
Average Volume (3M)1.43M
Market Cap
$2.27B
Enterprise Value$2.37K
Total Cash (Recent Filing)$94.57M
Total Debt (Recent Filing)$20.07M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 10, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding53,761,513
10 Day Avg. Volume1,094,003
30 Day Avg. Volume1,433,456
Financial Highlights & Ratios
PEG Ratio-2.01
Price to Book (P/B)11.70
Price to Sales (P/S)6.69
P/FCF Ratio-513.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$54.60Price Target Upside38.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.5
Revenue Forecast (FY)$270.88M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained mid-70% gross margins indicate durable product-level economics and pricing power for AxoGen’s allograft and adjunct products. Strong unit margins provide room to invest in commercial expansion and R&D, and improve leverage to operating profitability as revenue scales.
Positive Cash GenerationTTM positive operating and free cash flow marks a structural improvement versus prior periods, supplying internal capital for growth, clinical programs and strategic investments. Reliable cash generation reduces near-term financing needs and enhances operational flexibility.
Strengthened Balance SheetVery low leverage and a sizable equity base provide a lasting capital buffer for a loss-making but growing medtech. This balance-sheet strength supports sustained investment in commercialization, clinical trials and selective strategic deals without urgent refinancing pressure.
Bears Say
Ongoing Net LossesThe company remains unprofitable and has seen net margin deterioration year-over-year. Persistent losses can erode equity over time if not reversed, limit returns to shareholders, and require continued cash generation or financing to sustain growth and clinical investments.
Inconsistent Free Cash FlowAlthough FCF is currently positive, recent decline and weak cash conversion versus accounting losses show durability risk. If cash conversion stalls, AxoGen may face pressure funding trials, commercial expansion or strategic stakes without tapping external capital.
Reliance On Procedures, Reimbursement & Tissue SupplyBusiness fundamentally depends on procedure volumes, surgeon adoption, payer coverage and donated tissue supply. These structural exposures can limit consistent growth and margin expansion if reimbursement, referral patterns or donor supply tighten over the medium term.
AxoGen News
AXGN FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was $12.38 and its highest was $46.95 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $2.27B.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Nov 10, 2026 which is in 100 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Jul 29, 2026. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.121 by -$0.001.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $1 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.12.
How many shares outstanding does AxoGen have?
AxoGen has 53,761,513 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of $0.12 in its last earnings report, missing expectations of $0.121. Following the earnings report the stock price went up 0.535%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in AXGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AxoGen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.60 (38.26% Upside)
$54.60 (38.26% Upside)
Blogger Sentiment
Neutral
AXGN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 24.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
198.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.39%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
AXGN Company Deck
AXGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents materially positive operational and strategic progress: robust revenue growth (Q4 +21.3% YoY; FY +20.2% YoY), a strong capital raise and debt retirement, positive adjusted EBITDA and cash flow for the year, and a transformative FDA BLA approval that establishes Avance as the reference biologic. Near-term challenges include one-time BLA-related noncash charges, elevated operating expenses (notably R&D and G&A), a Q4 net loss and short-term gross margin pressure as the product mix shifts to the biologic. Management provided prudent guidance (≥18% revenue growth for 2026) and expects margin recovery in 2027 as scale and process improvements are implemented. Overall, the highlights outweigh the lowlights given the regulatory milestone, healthy top-line growth, improved adjusted EBITDA and strengthened balance sheet, supporting a constructive outlook despite short-term cost pressure.View all AXGN earnings summariesAXGN Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$54.60
▲(38.26% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
1.59% Insiders
20.03% Mutual Funds
10.14% Other Institutional Investors
53.45% Public Companies and
Individual Investors











